Last $65.84 USD
Change Today -0.66 / -0.99%
Volume 597.5K
HSP On Other Exchanges
New York
As of 2:32 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HSP) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/26/15 - $66.56
52 Week Low
03/27/14 - $40.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HOSPIRA INC (HSP)

hospira inc (HSP) Details

Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprises Biosimilars that include Retacrit, a biosimilar erythropoietin, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a post-operative pain management drug. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

17,000 Employees
Last Reported Date: 02/12/14
Founded in 2003

hospira inc (HSP) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.0M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $464.7K
Senior Vice President of Operations
Total Annual Compensation: $432.5K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $444.6K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $429.8K
Compensation as of Fiscal Year 2013.

hospira inc (HSP) Key Developments

Hospira Receives FDA Clearance for Plum 360 Infusion System

Hospira Inc. announced that the company has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum 360 infusion system with Hospira MedNet safety software. The newest in Hospira's portfolio of infusion devices, the Plum 360 system builds on the unique air management and secondary delivery features of Plum A+, while expanding its drug library and wireless capability to enable streamlined electronic medical record (EMR) integration. The Plum 360 infusion system with Hospira MedNet safety software is designed to help improve the safety and efficiency of intravenous (I.V.) medication administration, with benefits including: infusion programming that defaults to the Hospira MedNet drug library for advanced patient safety; large drug library capacity with fast keypad drug search for ease of programming; improved wireless communication to expedite drug library updates and optimize EMR connectivity with automated programming and documentation; smart secondary delivery, so the pump can differentiate between primary and secondary infusion lines and deliver each as intended; and unique air management that doesn't require disconnecting the administration set from the patient to clear the air from the line. Plum 360 will be fully available to customers in the United States in the coming weeks.

Hospira to Close Clayton Manufacturing Facility

Hospira announced on January 13, 2015 that it is closing its Clayton manufacturing facility and cutting jobs. The facility employed about 250 people. The closure, scheduled for the second half of 2015, means all products manufactured at the site will be discontinued or transferred to other Hospira locations or third parties. Hospira estimates the layoffs will mean $15 million in employee-related costs including severance.

Hospira Submits New Biologics License Application to U.S. FDA for Epoetin Alfa Biosimilar

Hospira Inc. announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Retacrit, a proposed biosimilar to Amgen's EPOGEN (epoetin alfa) and Janssen's PROCRIT (epoetin alfa). The biosimilar application was submitted on December 16, 2014, under the new 351(k) approval pathway created by the Biologics Price Competition and Innovation Act of 2009 (BPCIA). Biosimilars are biologic drugs that are highly similar to a reference biopharmaceutical product and demonstrate no clinically meaningful differences in terms of the safety, purity and potency of the product. Biosimilars offer high-quality, lower-cost alternatives to reference biologics.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSP:US $65.84 USD -0.66

HSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cintas Corp $80.39 USD +0.42
CR Bard Inc $177.90 USD -0.55
Grifols SA €36.50 EUR -0.13
Terumo Corp ¥2,882 JPY +64.00
UCB SA €70.01 EUR -0.43
View Industry Companies

Industry Analysis


Industry Average

Valuation HSP Industry Range
Price/Earnings 34.0x
Price/Sales 2.5x
Price/Book 3.4x
Price/Cash Flow 34.0x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at